Codexis ( (CDXS) ) has provided an announcement.
On March 28, 2025, Codexis, Inc. appointed Cynthia Collins as a Class II director on its Board of Directors, effective immediately. Ms. Collins, who is recognized as an independent director under Nasdaq rules, will also serve on the Compensation Committee. Her extensive experience includes roles as CEO of various biotech and healthcare companies, such as Editas Medicine and Human Longevity Inc. This strategic appointment is expected to enhance Codexis’s governance and operational oversight, leveraging Ms. Collins’s expertise in the biotech sector.
More about Codexis
YTD Price Performance: -43.80%
Average Trading Volume: 831,059
Technical Sentiment Signal: Buy
Current Market Cap: $232.8M
For a thorough assessment of CDXS stock, go to TipRanks’ Stock Analysis page.